Mesenchymal stem cells or mesenchymal stromal cells (MSCs) are a multipotent, heterogeneous population of cells that play a critical role in wound healing and tissue regeneration. MSCs, found in the tumor microenvironment, support tumor growth through the production of angiogenic factors, growth factors and extracellular matrix proteins. They also have immunomodulatory properties, and since they produce indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2) and transforming growth factor β (TGF-β), they have been thought to have primarily immunosuppressive effects. However, their role in the tumor microenvironment is complex and demonstrates plasticity depending on location, stimulatory factors and environment. The presence of melanoma-activated tumor-infiltrating lymphocytes (TILs) has been shown to produce pro-inflammatory changes with TH1 (type 1T helper)-like phenotype in MSCs via activated-TIL released cytokines such as interferon γ (IFN-γ), tumor necrosis factor α (TNF-α) and interleukin-1α (IL-1α), while simultaneously producing factors, such as IDO1, which have been traditionally associated with immunosuppression. Similarly, the combination of IFN-γ and TNF-α polarizes MSCs to a primarily TH1-like phenotype with the expression of immunosuppressive factors. Ultimately, further studies are encouraged and needed for a greater understanding of the role of MSCs in the tumor microenvironment and to improve cancer immunotherapy.
-
Cover Image
Cover Image
Mapping gene signatures according to their expression in different immune landscapes of breast (BRCA), lung (LUAD) and colon (COAD) carcinoma, and melanoma (SKCM); signatures selectively expressed in the immune-active (ICR4) landscape are shown in red, those selectively expressed in the immune-silent (ICR1) landscape are shown as blue and those that are ubiquitously expressed independent of immune landscape are white. The image is based on Figure 1 in this issue's opening article (Lu et al., pages 411–419) in which the authors look at how cancer cells go through a conserved evolutionary bottleneck facing a Two-Option Choice to evade recognition by the immune competent host: they can either adopt a clean oncogenic process devoid of immunogenic stimuli (immune-silent tumors) or display an entropic biology prone to immune recognition (immune-active tumors).
Mesenchymal stromal cell plasticity and the tumor microenvironment Available to Purchase
Francesco M. Marincola, Hee Joon Bae, Shutong Liu, Ping Jin, David Stroncek; Mesenchymal stromal cell plasticity and the tumor microenvironment. Emerg Top Life Sci 12 December 2017; 1 (5): 487–492. doi: https://doi.org/10.1042/ETLS20170141
Download citation file: